Pancreatic Cancer Research

ResearcherNational Cheng Kung University HospitalActive in the last 2 years

Chien‐Jui Huang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-5503-9266; OpenAlex author ID A5075156358. Sources: OpenAlex.

Their work

Papers
8 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
26
Papers, trials and grants by year

2022: 3 papers · 2023: 2 papers · 2024: 2 papers · 2025: none · 2026: 1 paper

Papers 8

  1. Improved survival with adding-on strategy after failure of nanoliposomal irinotecan plus 5-fluorouracil and leucovorin in metastatic pancreatic adenocarcinoma. First author DOI 10.1016/j.jfma.2025.02.035↗
  2. Systemic treatments in pancreatic cancer: Taiwan pancreas society recommendation. Co-author DOI 10.1016/j.bj.2023.100696↗
  3. Germline mutations of homologous recombination genes and clinical outcomes in pancreatic cancer: a multicenter study in Taiwan. Co-author DOI 10.1186/s12929-024-01008-7↗
  4. Investigation into the content of red material in EUS-guided pancreatic cancer biopsies. Co-author DOI 10.1016/j.gie.2023.01.041↗
  5. The experience of neoadjuvant chemotherapy versus upfront surgery in resectable pancreatic cancer: a cross sectional study. Co-author DOI 10.1097/js9.0000000000000495↗
  6. Cancer-cell-derived cell-free DNA can predict distant metastasis earlier in pancreatic cancer: a prospective cohort study. Co-author DOI 10.1177/17588359221106558↗
  7. The Differential Clinical Impacts of Cachexia and Sarcopenia on the Prognosis of Advanced Pancreatic Cancer. Co-author DOI 10.3390/cancers14133137↗
  8. Improved survival with induction chemotherapy and conversion surgery in locally advanced unresectable pancreatic cancer: a single institution experience. Co-author PMID 35693078↗

Closest collaborators

The 25 strongest of 26 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yan‐Shen Shan · 6 shared papers, 2022–2026 · strength 1.12
  2. Nai‐Jung Chiang · 6 shared papers, 2022–2024 · strength 0.99
  3. Yung‐Yeh Su · 5 shared papers, 2022–2024 · strength 0.88
  4. Ying‐Jui Chao · 5 shared papers, 2022–2024 · strength 0.80
  5. Li‐Tzong Chen · 3 shared papers, 2022–2024 · strength 0.47
  6. Shih‐Hung Yang · 1 shared paper, 2026 · strength 0.32
  7. Sung‐Hsin Kuo · 1 shared paper, 2026 · strength 0.32
  8. Kun‐Huei Yeh · 1 shared paper, 2026 · strength 0.32
  9. Hui‐Jen Tsai · 2 shared papers, 2022–2024 · strength 0.30
  10. Ping‐Jui Su · 2 shared papers, 2022–2023 · strength 0.29
  11. Ting‐Kai Liao · 2 shared papers, 2022–2023 · strength 0.29
  12. Bor‐Shyang Sheu · 1 shared paper, 2023 · strength 0.22
  13. Meng‐Ying Lin · 1 shared paper, 2023 · strength 0.22
  14. Wei‐Lun Chang · 1 shared paper, 2023 · strength 0.22
  15. Yen‐Yang Chen · 1 shared paper, 2024 · strength 0.19
  16. Jen‐Shi Chen · 1 shared paper, 2024 · strength 0.19
  17. Wen‐Chi Chou · 1 shared paper, 2024 · strength 0.19
  18. Hsin‐Chen Lin · 1 shared paper, 2024 · strength 0.19
  19. Tai‐Jan Chiu · 1 shared paper, 2024 · strength 0.19
  20. Li‐Yuan Bai · 1 shared paper, 2024 · strength 0.19
  21. Chung‐Pin Li · 1 shared paper, 2024 · strength 0.19
  22. Shih‐Hung Yang · 1 shared paper, 2024 · strength 0.19
  23. Siao Muk Cheng · 1 shared paper, 2024 · strength 0.17
  24. Jeffrey Shu-Ming Chang · 1 shared paper, 2024 · strength 0.17
  25. Ya‐Chin Hou · 1 shared paper, 2022 · strength 0.15

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.